Nuvilex's Pancreatic Cancer Treatment Readies to Challenge Eli Lilly and Celgene in Late-Phase Clinical Trials
19 févr. 2014 09h00 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Feb 19, 2014) - Nuvilex, Inc. (OTCQB: NVLX) is a small biotech firm in Silver Spring, Maryland, that hopes to soon be mentioned with much larger biotechnology and...
Nuvilex to Answer Increasing Calls for Better Pancreatic Cancer Treatment Without Gemcitabine
16 déc. 2013 09h15 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Dec 16, 2013) - Nuvilex, Inc. (OTCQB: NVLX) may be just what the National Cancer Institute (NCI) and a growing number of doctors ordered - the company's late stage...
Nuvilex, Inc. Reaches Unofficial Starting Line of Its Phase 3 Pancreatic Cancer Clinical Trials
05 nov. 2013 08h30 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Nov 5, 2013) - Nuvilex, Inc. (OTCQB: NVLX) made an announcement yesterday that should have investors excited that the company's Phase 3 clinical trials may have...
Nuvilex Eyes FDA Fast Track After ABRAXANE Approved for Pancreatic Cancer
11 sept. 2013 08h45 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Sep 11, 2013) - Nuvilex, Inc. (OTCQB: NVLX) and its shareholders enjoyed what could be a dress rehearsal of their own future with the Food and Drug Administration's...
FDA Approves ABRAXANE(R) for Pancreatic Cancer, Could Nuvilex's Treatment Be Next
09 sept. 2013 08h30 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Sep 9, 2013) - After presenting the results of its large scale Phase III clinical trial at the 2013 Gastrointestinal Cancers Symposium of the American Society of...
Nuvilex Investors Watch as Incyte Shares Rise Sharply on Pancreatic Cancer Trials Data
28 août 2013 08h30 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Aug 28, 2013) - As Nuvilex, Inc. (OTCQB: NVLX) continues to methodically build its brand as a biotechnology firm ahead of its future Phase III clinical trials for the...
Drug Makers Could Soon Turn Away From Eli Lilly's Gemzar and Toward Nuvilex's Cell Encapsulation
22 août 2013 08h30 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Aug 22, 2013) - While Eli Lilly's cancer fighting drug Gemzar (gemcitabine) has been on the market since the late 1990s, its success with cancer duly noted, other big...
Nuvilex, Inc. a Biotech Developing Treatments for Healthcare's Hard Targets
26 juin 2013 08h30 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Jun 26, 2013) - Nuvilex, Inc. (OTCQB: NVLX) executives aren't daunted by the statistics. As a matter of fact, they're aware the research they do is directed...
Nuvilex, Inc. and Celgene, Corp. Can Both Replace Eli Lilly's Cancer Drug Gemzar
20 mai 2013 08h30 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - May 20, 2013) - The race is on, and patients with advanced stage, inoperable pancreatic cancer will be the recipients of the winner's treatment. Two biotechnology...
Nuvilex, Inc. Pancreatic Cancer Therapy Offers Higher Survival Rate and Less Toxicity Than Competitors
02 mai 2013 08h30 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - May 2, 2013) - Nuvilex, Inc. (OTCQB: NVLX) has already produced impressive results from its two independent Phase II clinical trials in patients with advanced,...